Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 402-408

  Xie, H G ^a   Kim, R B ^a   Stein, C M ^a   Wilkinson, G R ^a   Wood, A J J ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

(S) mephenytoin hydroxylation; Black subjects; CYP2C19; Database; Genetic polymorphism; Meta analysis

Indexed keywords

4' HYDROXYMEPHENYTOIN; CYTOCHROME; MEPHENYTOIN; OMEPRAZOLE; PROGUANIL;

ALLELE; ARTICLE; DRUG METABOLISM; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NEGRO; PHENOTYPE; PRIORITY JOURNAL;

AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENOTYPE; HUMANS; HYDROXYLATION; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0032821754     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00009.x     Document Type: Article

References (44)

1. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989; 43: 53-76.
2. Bertilsson L. Geographic/interracial differences in polymorphic drug oxidation: current state of the knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.
3. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306: 240-245.
4. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S) -mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-1752.
5. de Morais SMF, Goldstein JA, Xie HG, et al. Generic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-411.
6. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant alleles. J Pharmacol Exp Ther 1997; 281: 604-609.
7. Ferguson RJ, de Morais SMF, Benhamou S, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284: 356-361.
8. Ibeanu GC, Goldstein JA, Meyer U, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian peter metabolizer of mephenytoin. J Pharmacol Exp Ther 1998; 286: 1490-1495.
9. Kaisary A, Smith P, Jacqz E, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47: 5488-5493.
10. Tsuneoka Y, Fukushima K, Matsuo Y, Ichikawa Y, Watanabe Y. Genetic analysis of the CYP2C19 gene in the Japanese population. Life Sci 1996; 59: 1711-1715.
11. May DG, Black CM, Olsen NJ, et al. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquine, and mephenytoin. Clin Pharmacol Ther 1990; 48: 286-295.
12. Flockhart DA, Clauw DJ, Sale EB, Hewett J, Woosley RL. Pharmacogenetic characteristics of the cosinophilia-myalgia syndrome. Clin Pharmacol Ther 1994; 56: 398-405.
13. Xie HG, Xu ZH, Luo X, Huang SL, Zeng FD, Zhou HH. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidative metabolism in Chinese populations: a meta-analysis. Pharmacogenetics 1996; 6: 235-238.
14. Reviriego J, Bertilsson L, Carrillo JA, Llerena A, Valdivielso MJ, Benítez J. Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations. Eur J Clin Pharmacol 1993; 44: 593-595.
15. Alván G, Bechtel P, Iselius L, Gunder-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-537.
16. Pollock BG, Perel JM, Kirshner M, Altieri LP, Yeager AL, Reynolds CF III. S-mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol 1991; 40: 609-611.
17. Watkins WM, Mberu E, Nevill CG, Ward SA, Breckenridge AM, Koech DK. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans Roy Soc Trop Med Hyg 1990; 84: 492-495.
18. Edeki TI, Goldstein JA, de Morais SMF, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 1996; 6: 357-360.
19. Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 1996; 60: 138-144.
20. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996; 6: 521-526.
21. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population in Zimbabwe. Clin Pharmacol Ther 1995; 57: 656-661.
22. Skjelbo E, Mutabingwa TK, Bygbjerg IB, Nielsen KK, Gram LF, Brøsen K. Chloroguanide metabolism in relation to the efficiency in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996; 59: 304-311.
23. Iyun AO, Tucker GT, Woods HF, Lennard MS. The 4-hydroxylation of (S) -mephenytoin in Nigerians: a population study. Br J Clin Pharmacol 1990; 30: 312P [(Abstract)].
24. Herrlin K, Masscle AY, Jande M, et al. Bantu Tanzanians have a decreased capacity, to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 1998; 64: 391-401.
25. Xie HG, Xu ZH, Ou Yang DS, et al. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 1997; 7: 503-514.
26. Xie HG. Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects. Clin Pharmacol Ther 1997; 62: 691-692 [Letter].
27. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans J Biol Chem 1994; 269: 15419-15422.
28. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
29. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian, and American black populations. Pharmacogenetics 1997; 7: 59-64.
30. Martin DE, Tran JQ, Flockhart DA, Jorkasky DK. Analysis of CYP2D6 and CYP2C19 genotypes in large African American and Caucasian populations. Clin Pharmacol Ther 1998; 63: 206 [(Abstract)].
31. D'Agostino RB, Weintraub M. Meta analysis: a method for synthesizing research. Clin Pharmacol Ther 1995; 58: 605-616.
32. Inaba T, Jurima M, Kalow W. Family studies of mephenytoin hydroxylation deficiency. Am J Hum Genet 1986; 38: 768-772.
33. Ward SA, Goto F, Nakamura K, Jacqz E, Wilkinson GR, Branch RA. S-mephenytoin 4-hydroxylase is inherited as an autosomal recessive trait in Japanese families. Clin Pharmacol Ther 1987; 42: 96-99.
34. Brosen K, de Morais SMF, Meyer UA, Goldstein JA. Multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995; 5: 312-317.
35. Xie HG. How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? Clin Pharmacol Ther 1998; 64: 575 [Letter].
36. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A4 isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37: 413-420.
37. Funck-Brentano C, Becquemont L, Leneveu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997; 280: 730-738.
38. Thummel KE, Wilkinson GR. In vitro and in vivo interactions involving human CYP3A, Ann Rev Pharmacol Toxicol 1998; 38: 389-430.
39. Ward SA, Watkins WM, Mberu E, et al. Intersubject variability in the metabolism of progaunit to the active metabolite cyclognanil in man. Br J Clin Pharmacol 1989; 17: 781-787.
40. Jeppesen U, Rasmussen BB, Brosen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997; 62: 279-286.
41. Masimirembwa CM, Gustafsson LL, Dahl ML, Abdi YA, Hasler JA. Lack of effect of chloroquine on debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotype. Br J Clin Pharmacol 1996; 41: 344-346.
42. Reed TE. Caucassian genes in American Negroes. Science 1969; 165: 762-768.
43. Ohashi K, Futura T, Kosuge K, et al. Disposition and effects of omeprazole are related to CYP2C19 genotype. Clin Phamacol Ther 1998; 63: 152 (abstract).
44. Futura T, Ohashi K, Kamata T, et al. Effect of generic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027-1030.